* GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES´ STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR COVID-19
* GILEAD SCIENCES INC - UNDERSTAND THAT TRIAL HAS MET ITS PRIMARY ENDPOINT AND THAT NIAID WILL PROVIDE DETAILED INFORMATION AT AN UPCOMING BRIEFING
* GILEAD SCIENCES INC - AWARE OF POSITIVE DATA EMERGING FROM NIAID'S STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR TREATMENT OF COVID-19
* GILEAD - REMDESIVIR IS NOT YET LICENSED/APPROVED ANYWHERE GLOBALLY AND HAS NOT YET BEEN DEMONSTRATED TO BE SAFE OR EFFECTIVE FOR TREATMENT OF COVID-19
* GILEAD SCIENCES - WILL SHARE ADDITIONAL REMDESIVIR DATA FROM OPEN-LABEL PHASE 3 SIMPLE TRIAL IN PATIENTS WITH SEVERE COVID-19 DISEASE SHORTLY
* GILEAD SCIENCES - SEES DATA AT END OF MAY FROM 2ND SIMPLE STUDY EVALUATING 5- AND 10-DAY DOSING DURATIONS OF REMDESIVIR IN PATIENTS WITH MODERATE COVID-19 DISEASE
* GILEAD - PHASE 3 SIMPLE TRIAL WILL PROVIDE INFORMATION ON IF SHORTER, 5-DAY DURATION OF THERAPY MAY HAVE SIMILAR EFFICACY AND SAFETY AS 10-DAY TREATMENT COURSE IN NIAID TRIAL Source text for 온라인바카라 Eikon: Further company coverage:
A Ciência & Ensino é uma publicação semestral destinada a professores de ciências do ensino fundamental e médio e seus formadores.
BRIEF-Gilead Sciences Says Aware Of Positive Data Emerging From...
por Rubye McCarthy (2020-05-25)
April 29 (Reuters) - Gilead Sciences Inc:* GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES´ STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR COVID-19
* GILEAD SCIENCES INC - UNDERSTAND THAT TRIAL HAS MET ITS PRIMARY ENDPOINT AND THAT NIAID WILL PROVIDE DETAILED INFORMATION AT AN UPCOMING BRIEFING
* GILEAD SCIENCES INC - AWARE OF POSITIVE DATA EMERGING FROM NIAID'S STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR TREATMENT OF COVID-19
* GILEAD - REMDESIVIR IS NOT YET LICENSED/APPROVED ANYWHERE GLOBALLY AND HAS NOT YET BEEN DEMONSTRATED TO BE SAFE OR EFFECTIVE FOR TREATMENT OF COVID-19
* GILEAD SCIENCES - WILL SHARE ADDITIONAL REMDESIVIR DATA FROM OPEN-LABEL PHASE 3 SIMPLE TRIAL IN PATIENTS WITH SEVERE COVID-19 DISEASE SHORTLY
* GILEAD SCIENCES - SEES DATA AT END OF MAY FROM 2ND SIMPLE STUDY EVALUATING 5- AND 10-DAY DOSING DURATIONS OF REMDESIVIR IN PATIENTS WITH MODERATE COVID-19 DISEASE
* GILEAD - PHASE 3 SIMPLE TRIAL WILL PROVIDE INFORMATION ON IF SHORTER, 5-DAY DURATION OF THERAPY MAY HAVE SIMILAR EFFICACY AND SAFETY AS 10-DAY TREATMENT COURSE IN NIAID TRIAL Source text for 온라인바카라 Eikon: Further company coverage: